User profiles for A.M. Richards
 | A Mark RichardsProfessor of Cardiology , National University of Singapore and University of Otago, New … Verified email at cdhb.health.nz Cited by 135604 |
A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction
…, DJ van Veldhuisen, HL Hillege, AM Richards… - Heart Failure, 2022 - jacc.org
Objectives This study sought to estimate and compare the aggregate treatment benefit of
pharmacological therapy for heart failure (HF) with reduced ejection fraction. Background The …
pharmacological therapy for heart failure (HF) with reduced ejection fraction. Background The …
Biology of the natriuretic peptides
A Martinez-Rumayor, AM Richards, JC Burnett… - The American journal of …, 2008 - Elsevier
The biology of the natriuretic peptide (NP) system is complex, yet highly phylogenetically
preserved. It regulates salt and water handling, promotes vasodilatation, and exerts favorable …
preserved. It regulates salt and water handling, promotes vasodilatation, and exerts favorable …
Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection: a collaborative meta-analysis
…, WF Peacock, C Pemberton, AM Richards… - Annals of internal …, 2017 - acpjournals.org
… Richards reports nonfinancial support from Roche Diagnostics during the conduct of the
study and personal fees from Roche Diagnostics outside the submitted work. Dr. Troughton …
study and personal fees from Roche Diagnostics outside the submitted work. Dr. Troughton …
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
…, TG Yandle, EA Espine, MG Nicholls, AM Richards - The Lancet, 2000 - thelancet.com
Background There is currently no objective practical guide to intensity of drug treatment for
individuals with heart failure. We hypothesised that pharmacotherapy guided by plasma …
individuals with heart failure. We hypothesised that pharmacotherapy guided by plasma …
Plasma N-terminal pro–brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial …
AM Richards, MG Nicholls, TG Yandle, C Frampton… - Circulation, 1998 - Am Heart Assoc
Background—Newly discovered circulating peptides, N-terminal pro–brain natriuretic peptide
(N-BNP) and adrenomedullin (ADM), were examined for prediction of cardiac function and …
(N-BNP) and adrenomedullin (ADM), were examined for prediction of cardiac function and …
B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction
AM Richards, MG Nicholls, EA Espiner, JG Lainchbury… - Circulation, 2003 - Am Heart Assoc
Background— A recent landmark report has demonstrated that plasma B-type natriuretic
peptide (BNP) measured in acute coronary syndromes independently predicts mortality, heart …
peptide (BNP) measured in acute coronary syndromes independently predicts mortality, heart …
Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment
PJ Hunt, AM Richards, MG Nicholls… - Clinical …, 1997 - Wiley Online Library
OBJECTIVE Human brain natriuretic peptide‐32 (BNP) (ie proBNP(77–108)), the mature
form of BNP and secreted predominantly by the cardiac ventricle, is formed from a high …
form of BNP and secreted predominantly by the cardiac ventricle, is formed from a high …
2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial
…, AS Maisel, SH Lim, A Lamanna, AM Richards - Journal of the American …, 2012 - jacc.org
Objectives : The purpose of this study was to determine whether a new accelerated diagnostic
protocol (ADP) for possible cardiac chest pain could identify low-risk patients suitable for …
protocol (ADP) for possible cardiac chest pain could identify low-risk patients suitable for …
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy
MA Passini, J Bu, AM Richards, C Kinnecom… - Science translational …, 2011 - science.org
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused
by mutations in the SMN1 gene that result in a deficiency of SMN protein. One approach to …
by mutations in the SMN1 gene that result in a deficiency of SMN protein. One approach to …
N-terminal pro–B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP–Assisted Treatment To Lessen …
…, AK Hamid, MG Nicholls, AM Richards - Journal of the American …, 2009 - jacc.org
Objectives : The purpose of this study was to compare the effects of N-terminal pro–B-type
natriuretic peptide (NT-proBNP)-guided therapy with those of intensive clinical management …
natriuretic peptide (NT-proBNP)-guided therapy with those of intensive clinical management …
